STRO-002, Sutro Biopharma’s experimental antibody-drug conjugate, continues to be safe and elicit promising responses in heavily pretreated patients with advanced ovarian cancer, according to the latest data from a Phase 1 clinical trial. Updated interim findings from the ongoing open-label study (NCT03748186) showed that 32% of women who were eligible for response analyses responded to STRO-002, when given at doses of 2.9 mg/kg or higher. “We are encouraged to see meaningful clinical benefit from STRO-002…
You must be logged in to read/download the full post.
The post STRO-002 Continues to Show Promise in Phase 1 Trial for Advanced Ovarian Cancer appeared first on BioNewsFeeds.